Shuai Zhang1, Jiaran Zhang1, Jun Guo1, Lu Si2, Xue Bai3. 1. Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China. 2. Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China. silu15_silu@126.com. 3. Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China. baixue5673@126.com.
Abstract
PURPOSE OF REVIEW: This review mainly focuses on the unique features and the development of available therapeutic options for mucosal melanoma in different treatment settings, i.e., neoadjuvant, adjuvant, and palliative. RECENT FINDINGS: Mucosal melanoma is distinct from cutaneous melanoma in epidemiology, clinical features, and molecular landscape, characterized by more aggressive biological behavior, lower mutational burden, more chromosomal structure variants, unique driver mutation profile, and distinct tumor microenvironment. Systemic therapy is generally less effective to mucosal melanoma than its cutaneous counterpart. Therapeutic landscape for mucosal melanoma has evolved substantially in recent years: with new targeted therapy options as well as combination therapies built on the backbone of anti-PD-1/PD-L1 antibodies available (esp. anti-angiogenic agent and PD-1/PD-L1 combination), which, based on early phase trial data, seem to be promising. Mucosal melanoma is unique and distinct from cutaneous subtype. Unraveling the unique features of mucosal melanoma is a key to improve clinical outcomes.
PURPOSE OF REVIEW: This review mainly focuses on the unique features and the development of available therapeutic options for mucosal melanoma in different treatment settings, i.e., neoadjuvant, adjuvant, and palliative. RECENT FINDINGS: Mucosal melanoma is distinct from cutaneous melanoma in epidemiology, clinical features, and molecular landscape, characterized by more aggressive biological behavior, lower mutational burden, more chromosomal structure variants, unique driver mutation profile, and distinct tumor microenvironment. Systemic therapy is generally less effective to mucosal melanoma than its cutaneous counterpart. Therapeutic landscape for mucosal melanoma has evolved substantially in recent years: with new targeted therapy options as well as combination therapies built on the backbone of anti-PD-1/PD-L1 antibodies available (esp. anti-angiogenic agent and PD-1/PD-L1 combination), which, based on early phase trial data, seem to be promising. Mucosal melanoma is unique and distinct from cutaneous subtype. Unraveling the unique features of mucosal melanoma is a key to improve clinical outcomes.
Authors: Elizabeth C Smyth; Marisa Flavin; Melissa P Pulitzer; Ginger J Gardner; Peter D Costantino; Dennis S Chi; Kita Bogatch; Paul B Chapman; Jedd D Wolchok; Gary K Schwartz; Richard D Carvajal Journal: J Clin Oncol Date: 2011-10-17 Impact factor: 44.544
Authors: B Lian; C L Cui; L Zhou; X Song; X S Zhang; D Wu; L Si; Z H Chi; X N Sheng; L L Mao; X Wang; B X Tang; X Q Yan; Y Kong; J Dai; S M Li; X Bai; N Zheng; C M Balch; J Guo Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: Yi Lin Teh; Wei Lin Goh; Sze Huey Tan; Grace Yong; Alisa Noor Hidayah Sairi; Khee Chee Soo; Johnny Ong; Claramae Chia; Grace Tan; Henry Soeharno; Mann Hong Tan; Michelle Chan; Selvarajan Sathiyamoorthy; Kesavan Sittampalam; Jonathan Teh; Francis Chin; Vijay Sethi; Melissa Teo; Richard Quek; Mohamad Farid Journal: Asia Pac J Clin Oncol Date: 2017-10-20 Impact factor: 2.601